Literature DB >> 21529896

Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.

Lies Persijn1, An-Sofie Decavele, Sofie Schouwers, Katrien Devreese.   

Abstract

INTRODUCTION: The laboratory diagnosis of antiphospholipid syndrome (APS) requires the demonstration of antiphospholipid antibodies (aPL): lupus anticoagulant (LAC) measured through coagulation assays, anticardiolipin IgG or IgM antibodies (aCL) and/or anti-β2glycoprotein I IgG or IgM antibodies (aβ2GPI), usually detected by ELISA.
MATERIALS AND METHODS: We evaluated the diagnostic value of aCL and aβ2GPI measured by a new automated system using the chemiluminescence principle, the immunoanalyzer Zenit RA (Menarini).
RESULTS: Results of aCL and aβ2GPI were correlated with the clinical background of the patients and with results of ELISA (n=314). Correlated to the clinical background sensitivity/specificity ranged for aCL IgG between 7.5-45.2% / 54.2-98.8%, for aCL IgM 3.4-5.5% / 89.9-94%, for aβ2GPI IgG 5.5-25.3% / 75.6-100% and aβ2GPI IgM 3.4-4.8% / 89.9-92.3%, depending on the cut-off used. Sensitivity with manufacturer's cut-offs was comparable to ELISA, except for aβ2GPI IgG with a significantly lower sensitivity compared to ELISA (5.5% vs 11.6%). In the APS patient population (n=30) sensitivity of aCL IgG and aβ2GPI IgG was higher measured by ELISA compared to Zenit RA (46.7% vs 30.0%, and 46.7% vs 26.7%, respectively). Agreement between Zenit RA results and ELISA results for the four parameters was moderate (Kappa-values ranging 0.509-0.565). Sensitivity was 38.5%, 53.3%, 40% and 69.2% for aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM, respectively, applying the highest cut-off value for Zenit RA, raising towards 64.3%, 100%, 57.1%, for aCL IgG, aCL IgM, aβ2GPI IgG, respectively, in a APS patient population.
CONCLUSIONS: The new technology of chemiluminescense for measuring aPL showed good performance characteristics. Interpretation of results with a cut-off value associated with a good discrimination for disease, resulted in a lower sensitivity for the diagnosis of APS for aβ2GPI IgG measured by Zenit RA assays compared to ELISA; sensitivity for aCL IgG was comparable to ELISA. Specificity for all parameters was high and comparable for aCL and aβ2GPI.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529896     DOI: 10.1016/j.thromres.2011.04.004

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

2.  Routine use of Zenit RA, a novel chemiluminescent immunoanalyzer in autoimmune disease diagnosis.

Authors:  P Ghillani; L Dufat; S Himeur; M Miyara; Z Amoura; L Musset
Journal:  Auto Immun Highlights       Date:  2012-03-21

Review 3.  "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome.

Authors:  Roberta Misasi; Antonella Capozzi; Agostina Longo; Serena Recalchi; Emanuela Lococo; Cristiano Alessandri; Fabrizio Conti; Guido Valesini; Maurizio Sorice
Journal:  J Immunol Res       Date:  2015-03-19       Impact factor: 4.818

4.  High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score.

Authors:  Smith Kungwankiattichai; Yupa Nakkinkun; Weerapat Owattanapanich; Theera Ruchutrakool
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification.

Authors:  Laura Vanoverschelde; Hilde Kelchtermans; Jacek Musial; Bas de Laat; Katrien M J Devreese
Journal:  Res Pract Thromb Haemost       Date:  2019-05-26

6.  "Non-criteria" antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort.

Authors:  Tingting Liu; Jieyu Gu; Liyan Wan; Qiongyi Hu; Jialin Teng; Honglei Liu; Xiaobing Cheng; Junna Ye; Yutong Su; Yue Sun; Jinfeng Zhou; Gary L Norman; Xuefeng Wang; Chengde Yang; Hui Shi
Journal:  Arthritis Res Ther       Date:  2020-02-21       Impact factor: 5.156

7.  Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort.

Authors:  Chaojun Hu; Siting Li; Zhijuan Xie; Hanxiao You; Hui Jiang; Yu Shi; Wanting Qi; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

8.  Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Ping Li; Yina Bai; Fengchun Zhang; Yongzhe Li
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.